{'fraction_non_alphanumeric': 0.017830609212481426, 'fraction_numerical': 0.019316493313521546, 'mean_word_length': 5.299065420560748, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Treatment of postsurgical thromboembolic complications.

Under randomized and controlled conditions, 37 orthopedic patients at high risk from thromboembolic complications were given dextran 40 (Rheomacrodex), in a dose of about 1 gm/kg of body weight per 24 hours, for 52 hours after surgery because of its beneficial effect on red blood cell aggregation. The visible aggregation and the elevation of fibrinogen level usually observed in these patients, as well as the incidence of thromboembolism, were found to be significantly reduced in the treated group when compared to in 36 controls. Dextran 40 proved to be useful in the prevention of postsurgical thromboembolism.